PolyPid Ltd. NASDAQ:PYPD

PolyPid Ltd. stock price today

$3.53
+0.63
+22.15%
Financial Health
0
1
2
3
4
5
6
7
8
9

PolyPid Ltd. stock price monthly change

-23.75%
month

PolyPid Ltd. stock price quarterly change

-23.75%
quarter

PolyPid Ltd. stock price yearly change

-27.75%
year

PolyPid Ltd. key metrics

Market Cap
23.87M
Enterprise value
13.43M
P/E
-0.22
EV/Sales
N/A
EV/EBITDA
-0.33
Price/Sales
N/A
Price/Book
1.40
PEG ratio
-0.03
EPS
-12.55
Revenue
N/A
EBITDA
-23.38M
Income
-24.24M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

PolyPid Ltd. stock price history

PolyPid Ltd. stock forecast

PolyPid Ltd. financial statements

Average Price Target
Last Year

$10

Potential upside: 183.28%

Based on estimate of 1 analysts
  • Analysts Price target

  • Financials & Ratios estimates

PolyPid Ltd. (NASDAQ:PYPD): Profit margin
Jun 2023 0 -5.83M
Sep 2023 0 -5.60M
Dec 2023 0 -6.35M
Mar 2024 0 -6.44M
PolyPid Ltd. (NASDAQ:PYPD): Debt to assets
Jun 2023 26263000 17.91M 68.22%
Sep 2023 20932000 17.39M 83.1%
Dec 2023 15372000 17.46M 113.64%
Mar 2024 25395000 18.25M 71.86%
PolyPid Ltd. (NASDAQ:PYPD): Cash Flow
Mar 2023 0 0 0
Jun 2023 0 0 0
Sep 2023 0 0 0
Dec 2023 0 0 0

PolyPid Ltd. alternative data

PolyPid Ltd. (NASDAQ:PYPD): Employee count
Aug 2023 57
Sep 2023 57
Oct 2023 57
Nov 2023 57
Dec 2023 57
Jan 2024 57
Feb 2024 57
Mar 2024 59
Apr 2024 59
May 2024 59
Jun 2024 59
Jul 2024 59

PolyPid Ltd. other data

0.51% -1.44%
of PYPD is owned by hedge funds
98.55K -281.92K
shares is hold by hedge funds
Patent
Application
Filling date: 2 Jun 2020 Issue date: 17 Sep 2020
Grant
Filling date: 27 Sep 2015 Issue date: 1 Sep 2020
Application
Filling date: 13 Feb 2020 Issue date: 27 Aug 2020
Grant
Filling date: 6 Sep 2018 Issue date: 16 Jun 2020
Grant
Filling date: 17 Feb 2015 Issue date: 5 Nov 2019
Insider Compensation
Mr. Amir Weisberg (1956) Chief Executive Officer & Director
$936,620
Dr. Noam Emanuel (1959) Chief Scientific Officer
$804,820
Ms. Dikla Czaczkes Akselbrad (1973) Executive Vice President & Chief Financial Officer
$565,170
Ms. Dalit Hazan (1971) Vice President of R&D and Regulatory Affairs
$232,950
Monday, 23 December 2024
globenewswire.com
Wednesday, 11 December 2024
globenewswire.com
Friday, 29 November 2024
globenewswire.com
Wednesday, 13 November 2024
seekingalpha.com
Thursday, 7 November 2024
globenewswire.com
Wednesday, 30 October 2024
globenewswire.com
Monday, 21 October 2024
globenewswire.com
Tuesday, 1 October 2024
globenewswire.com
Tuesday, 3 September 2024
globenewswire.com
Wednesday, 14 August 2024
seekingalpha.com
Thursday, 1 August 2024
globenewswire.com
Wednesday, 31 July 2024
globenewswire.com
Monday, 10 June 2024
globenewswire.com
Thursday, 9 May 2024
Seeking Alpha
Wednesday, 24 April 2024
GlobeNewsWire
Wednesday, 28 February 2024
GlobeNewsWire
Monday, 19 February 2024
Zacks Investment Research
Wednesday, 14 February 2024
Seeking Alpha
Wednesday, 31 January 2024
GlobeNewsWire
Sunday, 12 November 2023
Seeking Alpha
Friday, 22 September 2023
GlobeNewsWire
Wednesday, 9 August 2023
Seeking Alpha
Monday, 24 April 2023
GlobeNewsWire
Wednesday, 8 February 2023
Seeking Alpha
Tuesday, 31 January 2023
GlobeNewsWire
Thursday, 26 January 2023
PennyStocks
Tuesday, 24 January 2023
PennyStocks
Saturday, 12 November 2022
Seeking Alpha
Wednesday, 26 October 2022
GlobeNewsWire
Thursday, 29 September 2022
PennyStocks
  • What's the price of PolyPid Ltd. stock today?

    One share of PolyPid Ltd. stock can currently be purchased for approximately $3.53.

  • When is PolyPid Ltd.'s next earnings date?

    Unfortunately, PolyPid Ltd.'s (PYPD) next earnings date is currently unknown.

  • Does PolyPid Ltd. pay dividends?

    No, PolyPid Ltd. does not pay dividends.

  • How much money does PolyPid Ltd. make?

    PolyPid Ltd. has a market capitalization of 23.87M.

  • What is PolyPid Ltd.'s stock symbol?

    PolyPid Ltd. is traded on the NASDAQ under the ticker symbol "PYPD".

  • What is PolyPid Ltd.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of PolyPid Ltd.?

    Shares of PolyPid Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are PolyPid Ltd.'s key executives?

    PolyPid Ltd.'s management team includes the following people:

    • Mr. Amir Weisberg Chief Executive Officer & Director(age: 69, pay: $936,620)
    • Dr. Noam Emanuel Chief Scientific Officer(age: 66, pay: $804,820)
    • Ms. Dikla Czaczkes Akselbrad Executive Vice President & Chief Financial Officer(age: 52, pay: $565,170)
    • Ms. Dalit Hazan Vice President of R&D and Regulatory Affairs(age: 54, pay: $232,950)
  • How many employees does PolyPid Ltd. have?

    As Jul 2024, PolyPid Ltd. employs 59 workers.

  • When PolyPid Ltd. went public?

    PolyPid Ltd. is publicly traded company for more then 5 years since IPO on 26 Jun 2020.

  • What is PolyPid Ltd.'s official website?

    The official website for PolyPid Ltd. is polypid.com.

  • How can i contact PolyPid Ltd.?

    PolyPid Ltd. can be reached via phone at +972 74 719 5700.

  • What is PolyPid Ltd. stock forecast & price target?

    Based on 1 Wall Street analysts` predicted price targets for PolyPid Ltd. in the last 12 months, the avarage price target is $10. The average price target represents a 183.28% change from the last price of $3.53.

PolyPid Ltd. company profile:

PolyPid Ltd.

polypid.com
Exchange:

NASDAQ

Full time employees:

59

Industry:

Biotechnology

Sector:

Healthcare

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

18 Hasivim Street
Petah Tikva, 4959376

CIK: 0001611842
ISIN: IL0011326795
CUSIP: M8001Q118